Phase I study of GRN1005 in recurrent malignant glioma

Jan Drappatz, Andrew Brenner, Eric T. Wong, April Eichler, David Schiff, Morris D. Groves, Tom Mikkelsen, Steve Rosenfeld, John Sarantopoulos, Christina A. Meyers, Robert M. Fielding, Kelly Elian, Xiaolin Wang, Betty Lawrence, Mona Shing, Stephen Kelsey, Jean Paul Castaigne, Patrick Y. Wen

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Purpose: GRN1005 is a peptide-drug conjugate with the ability to penetrate the blood-brain barrier (BBB) and tumor cells by targeting the low-density lipoprotein receptor-related protein-1. We conducted a first-in-human phase I trial of GRN1005 in patients with recurrent glioma. Methods: Patients received GRN1005 by intravenous infusion every 3 weeks. Doses were escalated using a modified Fibonacci scheme. Study objectives included safety, tolerability, identification of the maximum tolerated dose (MTD), pharmacokinetics, and preliminary evidence of efficacy. Tumor extracted from patients undergoing surgery following administration of GRN1005 was analyzed to determine whether therapeutic concentrations of GRN1005 were achieved. Results: Sixty-three patients received GRN1005 at doses of 30 to 700 mg/m2 every 3 weeks. Therapy was well tolerated with neutropenia, leucopenia, and fatigue as the most frequent drug-associated grade 3/4 or higher toxicities. The MTD was 650 mg/m2 every 3 weeks. Dose-limiting toxicities were grade 3 mucositis and grade 4 neutropenia. There was no evidence of central nervous system toxicity or antibody production. Pharmacokinetic analysis showed that exposure to GRN1005 was dose proportional. We observed one complete and two partial responses. Eight of 27 patients dosed ≥420 mg/m2 had stable disease, which lasted a median of 51 days. Therapeutic concentrations ofGRN1005and free paclitaxel were shown in tumor tissue of surgical patients dosed with ≥200 mg/m2. Conclusion: GRN1005 delivers paclitaxel across the BBB and achieves therapeutic concentrations in tumor tissue. It has similar toxicity to paclitaxel and appears to have activity in recurrent glioma. The recommended phase II dose is 650 mg/m2 every 3 weeks.

Original languageEnglish (US)
Pages (from-to)1567-1576
Number of pages10
JournalClinical Cancer Research
Volume19
Issue number6
DOIs
StatePublished - Mar 15 2013

Fingerprint

Glioma
Paclitaxel
Maximum Tolerated Dose
Neutropenia
Blood-Brain Barrier
Pharmacokinetics
Low Density Lipoprotein Receptor-Related Protein-1
Neoplasms
Mucositis
paclitaxel-Angiopep-2 conjugate
Leukopenia
Therapeutics
Intravenous Infusions
Brain Neoplasms
Pharmaceutical Preparations
Antibody Formation
Fatigue
Central Nervous System
Safety
Peptides

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Drappatz, J., Brenner, A., Wong, E. T., Eichler, A., Schiff, D., Groves, M. D., ... Wen, P. Y. (2013). Phase I study of GRN1005 in recurrent malignant glioma. Clinical Cancer Research, 19(6), 1567-1576. https://doi.org/10.1158/1078-0432.CCR-12-2481

Phase I study of GRN1005 in recurrent malignant glioma. / Drappatz, Jan; Brenner, Andrew; Wong, Eric T.; Eichler, April; Schiff, David; Groves, Morris D.; Mikkelsen, Tom; Rosenfeld, Steve; Sarantopoulos, John; Meyers, Christina A.; Fielding, Robert M.; Elian, Kelly; Wang, Xiaolin; Lawrence, Betty; Shing, Mona; Kelsey, Stephen; Castaigne, Jean Paul; Wen, Patrick Y.

In: Clinical Cancer Research, Vol. 19, No. 6, 15.03.2013, p. 1567-1576.

Research output: Contribution to journalArticle

Drappatz, J, Brenner, A, Wong, ET, Eichler, A, Schiff, D, Groves, MD, Mikkelsen, T, Rosenfeld, S, Sarantopoulos, J, Meyers, CA, Fielding, RM, Elian, K, Wang, X, Lawrence, B, Shing, M, Kelsey, S, Castaigne, JP & Wen, PY 2013, 'Phase I study of GRN1005 in recurrent malignant glioma', Clinical Cancer Research, vol. 19, no. 6, pp. 1567-1576. https://doi.org/10.1158/1078-0432.CCR-12-2481
Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, Groves MD et al. Phase I study of GRN1005 in recurrent malignant glioma. Clinical Cancer Research. 2013 Mar 15;19(6):1567-1576. https://doi.org/10.1158/1078-0432.CCR-12-2481
Drappatz, Jan ; Brenner, Andrew ; Wong, Eric T. ; Eichler, April ; Schiff, David ; Groves, Morris D. ; Mikkelsen, Tom ; Rosenfeld, Steve ; Sarantopoulos, John ; Meyers, Christina A. ; Fielding, Robert M. ; Elian, Kelly ; Wang, Xiaolin ; Lawrence, Betty ; Shing, Mona ; Kelsey, Stephen ; Castaigne, Jean Paul ; Wen, Patrick Y. / Phase I study of GRN1005 in recurrent malignant glioma. In: Clinical Cancer Research. 2013 ; Vol. 19, No. 6. pp. 1567-1576.
@article{96d446af0f794eaaadd0068ec8ab16f1,
title = "Phase I study of GRN1005 in recurrent malignant glioma",
abstract = "Purpose: GRN1005 is a peptide-drug conjugate with the ability to penetrate the blood-brain barrier (BBB) and tumor cells by targeting the low-density lipoprotein receptor-related protein-1. We conducted a first-in-human phase I trial of GRN1005 in patients with recurrent glioma. Methods: Patients received GRN1005 by intravenous infusion every 3 weeks. Doses were escalated using a modified Fibonacci scheme. Study objectives included safety, tolerability, identification of the maximum tolerated dose (MTD), pharmacokinetics, and preliminary evidence of efficacy. Tumor extracted from patients undergoing surgery following administration of GRN1005 was analyzed to determine whether therapeutic concentrations of GRN1005 were achieved. Results: Sixty-three patients received GRN1005 at doses of 30 to 700 mg/m2 every 3 weeks. Therapy was well tolerated with neutropenia, leucopenia, and fatigue as the most frequent drug-associated grade 3/4 or higher toxicities. The MTD was 650 mg/m2 every 3 weeks. Dose-limiting toxicities were grade 3 mucositis and grade 4 neutropenia. There was no evidence of central nervous system toxicity or antibody production. Pharmacokinetic analysis showed that exposure to GRN1005 was dose proportional. We observed one complete and two partial responses. Eight of 27 patients dosed ≥420 mg/m2 had stable disease, which lasted a median of 51 days. Therapeutic concentrations ofGRN1005and free paclitaxel were shown in tumor tissue of surgical patients dosed with ≥200 mg/m2. Conclusion: GRN1005 delivers paclitaxel across the BBB and achieves therapeutic concentrations in tumor tissue. It has similar toxicity to paclitaxel and appears to have activity in recurrent glioma. The recommended phase II dose is 650 mg/m2 every 3 weeks.",
author = "Jan Drappatz and Andrew Brenner and Wong, {Eric T.} and April Eichler and David Schiff and Groves, {Morris D.} and Tom Mikkelsen and Steve Rosenfeld and John Sarantopoulos and Meyers, {Christina A.} and Fielding, {Robert M.} and Kelly Elian and Xiaolin Wang and Betty Lawrence and Mona Shing and Stephen Kelsey and Castaigne, {Jean Paul} and Wen, {Patrick Y.}",
year = "2013",
month = "3",
day = "15",
doi = "10.1158/1078-0432.CCR-12-2481",
language = "English (US)",
volume = "19",
pages = "1567--1576",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Phase I study of GRN1005 in recurrent malignant glioma

AU - Drappatz, Jan

AU - Brenner, Andrew

AU - Wong, Eric T.

AU - Eichler, April

AU - Schiff, David

AU - Groves, Morris D.

AU - Mikkelsen, Tom

AU - Rosenfeld, Steve

AU - Sarantopoulos, John

AU - Meyers, Christina A.

AU - Fielding, Robert M.

AU - Elian, Kelly

AU - Wang, Xiaolin

AU - Lawrence, Betty

AU - Shing, Mona

AU - Kelsey, Stephen

AU - Castaigne, Jean Paul

AU - Wen, Patrick Y.

PY - 2013/3/15

Y1 - 2013/3/15

N2 - Purpose: GRN1005 is a peptide-drug conjugate with the ability to penetrate the blood-brain barrier (BBB) and tumor cells by targeting the low-density lipoprotein receptor-related protein-1. We conducted a first-in-human phase I trial of GRN1005 in patients with recurrent glioma. Methods: Patients received GRN1005 by intravenous infusion every 3 weeks. Doses were escalated using a modified Fibonacci scheme. Study objectives included safety, tolerability, identification of the maximum tolerated dose (MTD), pharmacokinetics, and preliminary evidence of efficacy. Tumor extracted from patients undergoing surgery following administration of GRN1005 was analyzed to determine whether therapeutic concentrations of GRN1005 were achieved. Results: Sixty-three patients received GRN1005 at doses of 30 to 700 mg/m2 every 3 weeks. Therapy was well tolerated with neutropenia, leucopenia, and fatigue as the most frequent drug-associated grade 3/4 or higher toxicities. The MTD was 650 mg/m2 every 3 weeks. Dose-limiting toxicities were grade 3 mucositis and grade 4 neutropenia. There was no evidence of central nervous system toxicity or antibody production. Pharmacokinetic analysis showed that exposure to GRN1005 was dose proportional. We observed one complete and two partial responses. Eight of 27 patients dosed ≥420 mg/m2 had stable disease, which lasted a median of 51 days. Therapeutic concentrations ofGRN1005and free paclitaxel were shown in tumor tissue of surgical patients dosed with ≥200 mg/m2. Conclusion: GRN1005 delivers paclitaxel across the BBB and achieves therapeutic concentrations in tumor tissue. It has similar toxicity to paclitaxel and appears to have activity in recurrent glioma. The recommended phase II dose is 650 mg/m2 every 3 weeks.

AB - Purpose: GRN1005 is a peptide-drug conjugate with the ability to penetrate the blood-brain barrier (BBB) and tumor cells by targeting the low-density lipoprotein receptor-related protein-1. We conducted a first-in-human phase I trial of GRN1005 in patients with recurrent glioma. Methods: Patients received GRN1005 by intravenous infusion every 3 weeks. Doses were escalated using a modified Fibonacci scheme. Study objectives included safety, tolerability, identification of the maximum tolerated dose (MTD), pharmacokinetics, and preliminary evidence of efficacy. Tumor extracted from patients undergoing surgery following administration of GRN1005 was analyzed to determine whether therapeutic concentrations of GRN1005 were achieved. Results: Sixty-three patients received GRN1005 at doses of 30 to 700 mg/m2 every 3 weeks. Therapy was well tolerated with neutropenia, leucopenia, and fatigue as the most frequent drug-associated grade 3/4 or higher toxicities. The MTD was 650 mg/m2 every 3 weeks. Dose-limiting toxicities were grade 3 mucositis and grade 4 neutropenia. There was no evidence of central nervous system toxicity or antibody production. Pharmacokinetic analysis showed that exposure to GRN1005 was dose proportional. We observed one complete and two partial responses. Eight of 27 patients dosed ≥420 mg/m2 had stable disease, which lasted a median of 51 days. Therapeutic concentrations ofGRN1005and free paclitaxel were shown in tumor tissue of surgical patients dosed with ≥200 mg/m2. Conclusion: GRN1005 delivers paclitaxel across the BBB and achieves therapeutic concentrations in tumor tissue. It has similar toxicity to paclitaxel and appears to have activity in recurrent glioma. The recommended phase II dose is 650 mg/m2 every 3 weeks.

UR - http://www.scopus.com/inward/record.url?scp=84875125427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875125427&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-12-2481

DO - 10.1158/1078-0432.CCR-12-2481

M3 - Article

VL - 19

SP - 1567

EP - 1576

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -